Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWARD-JPN dulaglutide dose-comparison study in Japanese adults with type 2 diabetes
jRCT2031210019Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in HbA1c at Week 26. Started Apr 2021; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031210019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210019.